HepaRegeniX hits safety landmark in liver disease drug trial
HepaRegeniX reported that the first patient undergoing major liver resection for colorectal cancer liver metastases completed a 28-day treatment with darizmetinib in the second pilot part of its ongoing Phase 1b/2a study. Darizmetinib has demonstrated a favorable safety profile to date, with no trea
<p>HepaRegeniX reported that the first patient undergoing major liver resection for colorectal cancer liver metastases completed a 28-day treatment with darizmetinib in the second pilot part of its ongoing Phase 1b/2a study. Darizmetinib has demonstrated a favorable safety profile to date, with no trea</p>